Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Eli Lilly and Co | 905.5B | 117.3x | +12.51% |
AbbVie Inc | 348.9B | 66.1x | -6.05% |
AstraZeneca PLC | 267.8B | 42.0x | +17.52% |
Novartis AG | 259.3B | 24.2x | -5.59% |
Amgen Inc | 176.7B | 56.6x | -0.22% |
Merck & Co Inc | 295.6B | 21.6x | -43.23% |
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $905.5B |
---|---|
Revenue (TTM) | $38.9B |
Shares Outstanding | 950.4M |
Dividend Yield | 0.55% |
Annual Dividend Rate | 5.2000 USD |
Ex-Dividend Date | 08-15-24 |
Pay Date | 09-10-24 |
Beta | 0.42 |
EPS | $8.12 |
Book Value | $11.35 |
P/E Ratio | 117.3x |
Price/Sales (TTM) | 23.3 |
Price/Cash Flow (TTM) | 101.1x |
Operating Margin | 23.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.